GlassScriptPhysician profile
Aradhana Addepalli
NPI 1235213315
$2,757.01
in general payments reported to CMS, 2019-2025
26 companies · $1,161 in 2025
The $1,161 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $846 · 2020: $388 · 2021: $289 · 2023: $73.20 · 2025: $1,161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $832 · Travel and Lodging: $402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $832.28 |
| Travel and Lodging | $402.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $639.81 | 2021-2025 | Minimed 780g |
| Novo Nordisk INC | $545.71 | 2019-2025 | Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $208.26 | 2019-2020 | |
| Lilly USA, LLC | $195.04 | 2019-2025 | Jardiance |
| Amgen INC. | $163.78 | 2019-2025 | Tepezza, Evenity, Prolia |
| Cardiovascular Systems INC. | $149.79 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $106.02 | 2019-2020 | |
| Recordati_rare_diseases_inc. | $84.50 | 2025 | Isturisa |
| Becton, Dickinson and Company | $81.67 | 2019-2021 | |
| Medtronic Minimed, INC. | $66.56 | 2019-2020 | |
| Corcept Therapeutics | $63.65 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $63.18 | 2020-2021 | |
| Amarin Pharma, INC. | $46.68 | 2020-2021 | |
| Ipsen Biopharmaceuticals, INC | $42.05 | 2019-2021 | |
| Dexcom, INC. | $40.87 | 2023 | Dexcom G6 Transmitter |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $37.94 | 2025 | |
| Pfizer INC. | $37.55 | 2019-2020 | |
| Insulet Corporation | $33.64 | 2019 | |
| Radius Health, INC. | $32.68 | 2020-2025 | Tymlos |
| Chiesi USA, INC. | $19.52 | 2025 | Mycapssa |
| Abbott Laboratories | $17.95 | 2023 | Proclaim |
| Tolmar, INC. | $17.78 | 2025 | Fensolvi |
| Alexion Pharmaceuticals, INC. | $16.25 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.96 | 2020 | |
| Insmed, INC. | $15.53 | 2021 | |
| Horizon Therapeutics Plc | $14.64 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aradhana Addepalli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.